Malaria is a mosquito-borne parasitic infectious disease caused by Plasmodium species and remains a major global health threat, especially in endemic tropical regions. The WHO African Region carries the overwhelming majority of global malaria burden.
Novartis introduced new long-term social impact and sustainability targets covering access, global health, emissions, waste and water. The plan includes a 2030 access goal and net-zero across the value chain by 2040.
WHO has prequalified Coartem Baby, the first malaria treatment developed for newborns and young infants weighing 2 to 5 kilograms. The decision opens access through public procurement and donor-funded programs.
Australia's National Health and Medical Research Council marks 90 years of funding medical breakthroughs while facing warnings that research institutes could exhaust capital within a decade. The NHMRC's success includes funding the HPV vaccine that put Australia on track to eliminate cervical cancer by 2035, but sustained funding is needed to maintain world-class research capabilities.
India launches ₹10,000 crore Biopharma SHAKTI initiative to transform from generics manufacturing to innovation-led biologics leadership. The national mission aims to capture 5% of global biopharmaceutical market while addressing structural challenges in drug discovery and AI adoption.
Three new computational approaches enhance molecular property prediction and drug design through advanced neural networks, multimodal learning, and thermodynamic analysis of receptor-ligand interactions.
California-based Centivax has begun dosing participants in a Phase 1A clinical trial of Centi-Flu 01, a universal influenza vaccine designed to target conserved viral regions across all flu strains. Initial data from approximately 180 participants is expected within the year.
Isomorphic Labs introduced IsoDDE, a drug discovery engine that outperforms AlphaFold 3 by a factor of two in prediction accuracy. Google also updated Gemini 3 Deep Think, which now outperforms competing models in complex scientific tasks.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07548021 |
Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda |
NOT_YET_RECRUITING | PHASE1 |
| NCT07470424 |
A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults |
NOT_YET_RECRUITING | PHASE1 |
| NCT07468526 |
An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria |
NOT_YET_RECRUITING | PHASE3 |
| NCT07430592 |
This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria |
NOT_YET_RECRUITING | PHASE2 |
| NCT07416461 |
Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease |
RECRUITING | |
| NCT07387341 |
Long-acting Spatial Emanators / Repellents (LASER) |
NOT_YET_RECRUITING | NA |
| NCT07358910 |
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective |
RECRUITING | |
| NCT07358767 |
Impact of Malaria Mass Drug Administration on Malaria Prevalence in Under 15 Children and Pregnant Women |
COMPLETED | NA |
| NCT07246525 |
Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission |
NOT_YET_RECRUITING | PHASE4 |
| NCT07208760 |
L9LS-R21 Interaction |
WITHDRAWN | PHASE2 |
